Sign in
Taking peoplePhase 2

Triamcinolone acetonide placed inside the inner ear for sudden hearing loss

Tests triamcinolone acetonide in the inner ear for lasting sudden hearing loss.

Key facts

Who runs it
Medical University Of Vienna
Where
Austria1 site in 1 countryChoose a country to see its sites
Registry title
Intracochlear Triamcinolone acetonide in sudden sensorineural hearing loss patients - a prospective observer blinded randomized study
Status
Recruiting
Phase
Phase 2
People taking part
40 people, planned
Started
11 Dec 2024
Planned end
17 Apr 2026
Type of study
Interventional
Record updated
11 December 2024

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with sudden hearing loss of the inner ear that did not get better with steroid treatment. It tests triamcinolone acetonide placed inside the inner ear (cochlea).

Age
18 to 80 years
Sex
All sexes can join.
Disease stage
Sudden sensorineural hearing loss that started within 21 days. Hearing loss of ≥30dB in three neighbouring frequencies, and an average hearing threshold of ≥70dB at 0.5, 1, 2 and 4 kHz.
Earlier treatment
Hearing must not have recovered after standard treatment with steroids given by mouth or vein and steroids injected into the ear. People on long-term corticosteroid therapy cannot join.

Main reasons for not taking part

  • Pregnancy or breastfeeding
  • Earlier conductive hearing loss on the same side (air-bone gap >10dB), or other ear diseases such as Menière's disease or vestibular schwannoma
  • Sudden hearing loss on the same side within the last 12 months, or a suspected or found tear of the round window membrane
  • Disorders of the central nervous system or certain body-wide diseases
  • Current use of ear-harming drugs, such as aminoglycosides, cisplatin, loop diuretics, sildenafil, or immunosuppressive drugs

The registry criteria, word for word

Show all 16 criteriaShow less

Who can take part

  • Patients between 18 and 80 years within 21 days beginning from the onset of SSHL
  • Failed recovery after conservative treatment (systemic and intratympanic steroids) due to persisting SSHL
  • Patients with SSHL with a mean hearing threshold shift of ≥30dB in three adjacent frequencies (0.125, 0.25, 0.5, 1, 2, 4, 8 kHz)
  • Patients with an absolute mean hearing threshold of ≥70dB in the frequencies 0.5, 1, 2 and 4 kHz
  • Patients who signed the informed consent

Who cannot take part

  • Patients under permanent corticosteroid therapy
  • Ongoing treatment with aminoglycosides (e.g. gentamicin), erythromycin, tetracycline, chemotherapeutic agents (e.g. cisplatin, 5- fluorouracil, bleomycin), high-dose aspirin (6 to 8 g/day), phosphodiesterase 5 inhibitors (e.g. sildenafil), antimalarial medications (e. g. quinine and chloroquine), loop diuretics (e.g. furosemide, torasemid, acetazolamide), immunosuppressive drugs
  • Other ear diseases systemic or otologic (e.g. middle ear diseases, vestibular schwannoma, fluctuating hearing loss, Menière ́s Disease)
  • Central nervous disorders
  • Certain systemic diseases
  • Missing informed consent
  • Preexisting conductive hearing loss on the affected side (mean air- bone gap >10dB in the frequencies 0.5, 1, 2 and 4 kHz)
  • Pregnancy or nursing
  • Patients with hearing loss due to a (suspected) rupture of the round window membrane according to their history
  • Patients with an intraoperatively detected leak of the round window membrane
  • Repetitive SSHL within the last 12 months on the same side

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Evaluation of the effect of intracochlear application of triamcinolone acetonide on hearing function measured by the pure tone audiometry, in the treatment of patients with persistent sudden sensorineural hearing loss (SSHL) after unsuccessful conservative therapy.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
Intracochlear Triamcinolone acetonide in sudden sensorineural hearing loss patients - a prospective observer blinded randomized study
Plain-language title
Triamcinolone acetonide placed inside the inner ear for sudden hearing lossGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
11 December 2024